Replies to post #8688 on Mast Therapeutics Inc (fka MSTX)

[ExPatriate57]

LastLurker

I understand that they haven't begun the stability testing on 514 yet.

That's an important distinction. Unless they don't have a clear picture of what the FDA wants in the way of an approach to "stability testing", it wouldn't make sense to wait.

I figured the meeting was more about confirming Adventrx's understanding of *exactly* what the FDA was looking for from a presentation standpoint. not from a collection standpoint. But I have no empirical evidence to support that feeling.

Any easy way for us to figure out this important distinction? It makes a significant (~ one year) difference in the length of time before we see the "big numbers".

TIA and as always, GLTA

[LastLurker]

Cully just said in the conference that the recent shelving IS to finance the Phase III study of their target acquisition.

-The Last Lurker-